For further expansion of eligibility, the cancer biological marker alpha‐fetoprotein (AFP) was combined with tumor burdens, leading to proposals such as the AFP model,16 TTV/AFP,17 HALT‐HCC,18 and Metroticket 2.0.19 Here, AFP is linked to neoplasm.